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Abstract
Background: Signaling through the mTOR pathway contributes to growth, progression and chemoresistance of several
cancers. Accordingly, inhibitors have been developed as potentially valuable therapeutics. Their optimal development
requires consideration of dose, regimen, biomarkers and a rationale for their use in combination with other agents. Using
the infrastructure of the Comparative Oncology Trials Consortium many of these complex questions were asked within a
relevant population of dogs with osteosarcoma to inform the development of mTOR inhibitors for future use in pediatric
osteosarcoma patients.
Methodology/Principal Findings: This prospective dose escalation study of a parenteral formulation of rapamycin sought
to define a safe, pharmacokinetically relevant, and pharmacodynamically active dose of rapamycin in dogs with
appendicular osteosarcoma. Dogs entered into dose cohorts consisting of 3 dogs/cohort. Dogs underwent a pre-treatment
tumor biopsy and collection of baseline PBMC. Dogs received a single intramuscular dose of rapamycin and underwent 48-
hour whole blood pharmacokinetic sampling. Additionally, daily intramuscular doses of rapamycin were administered for 7
days with blood rapamycin trough levels collected on Day 8, 9 and 15. At Day 8 post-treatment collection of tumor and
PBMC were obtained. No maximally tolerated dose of rapamycin was attained through escalation to the maximal planned
dose of 0.08 mg/kg (2.5 mg/30kg dog). Pharmacokinetic analysis revealed a dose-dependent exposure. In all cohorts
modulation of the mTOR pathway in tumor and PBMC (pS6RP/S6RP) was demonstrated. No change in pAKT/AKT was seen
in tumor samples following rapamycin therapy.
Conclusions/Significance: Rapamycin may be safely administered to dogs and can yield therapeutic exposures. Modulation
pS6RP/S6RP in tumor tissue and PBMCs was not dependent on dose. Results from this study confirm that the dog may be
included in the translational development of rapamycin and potentially other mTOR inhibitors. Ongoing studies of
rapamycin in dogs will define optimal schedules for their use in cancer and evaluate the role of rapamycin use in the setting
of minimal residual disease.
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Introduction
Signaling through the mTOR pathway has been linked to
growth, progression and chemoresistance of several cancers
[1,2,3,4,5,6,7,8,9,10,11]. Accordingly, agents that act against this
pathway have been considered as potentially valuable therapeutics
for cancer. Rapamycin, the originally described mTOR pathway
inhibitor, is currently approved as an immunosuppressive agent
used during preparatory and maintenance regimens for organ and
bone marrow transplant patients. Preclinical studies of rapamycin
in mice as well as recent data using novel and approved rapalogs
(Ridaforolimus, Ariad; Temsirolimus, Wyeth) [12] in human
patients suggest that mTOR blockade may be active in several
cancers including sarcoma [2,13,14,15,16]. Based on responses in
sarcomas, phase II/III clinical trials of rapalogs have been initiated
in this patient population. The development of mTOR inhibitors
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e11013as agents for sarcoma patients requires optimization of dose and
regimen, defining informative biomarkers of effective exposure
and activity, and rationale for their use in combination with
existing or other novel drugs. An integrated and comparative
approach that includes dogs with naturally occurring sarcoma may
be uniquely suited to inform these development questions.
The mTOR pathway is the ‘‘nutrient sensor’’ of the cell and
proximate targets of the pathway are responsible for both terminal
oligopyrimidine (TOP) and cap-dependent translation of proteins
(Figure 1) [17]. Many of these proteins have been shown to be
important in cancer progression, angiogenesis, autophagy and
anti-apoptotic mechanisms [3,18,19,20]. Rapamycin inhibits
mTOR (via TORC1) following the formation of a complex with
FKBP-12 [17]. This results in decreased mTOR kinase activity,
inhibited phosphorylation of downstream targets such as p70
ribosomal protein S6 kinase (S6RP) and 4E-binding protein (4E-
BP1), and potentially suppression of ribosome biogenesis and
protein translation [3,17]. Interestingly, in some cancer histologies
up-regulation of pAKT following mTOR inhibition has been seen
both in preclinical models and in patients on receiving rapalogs in
clinical trials. Since up-regulation of AKT can be predictor of
chemoresistance and an aggressive phenotype this observation
requires further investigation in a clinically relevant setting
[21,22].
Work by us and others have highlighted the importance of the
mTOR pathway and the therapeutic benefit associated with
mTOR inhibition in several cancers including pediatric sarcomas
[2,13,14,23]. Early phase clinical studies using rapamycin or
rapamycin analogues (rapalogs) in pediatric sarcoma are currently
underway. As discussed above the development of rapamycin and
other rapalogs for use in pediatric osteosarcoma will require
information on the optimal schedule and regimen for rapamycin,
to understand the consequences of immunosuppression in patients,
and the potential utility of rapamycin in the setting of minimal
residual disease. Studies in dogs with osteosarcoma are well
positioned to address these development concerns generating
relevant translational data to inform the planned design of phase
II/III pediatric rapalogs trials.
Although not rigorously reported in the literature, there has
been a concern about a unique sensitivity of dogs to rapamycin
[24,25]. This sensitivity appears to include vasculitis (seen in most
mammalian species), particularly manifested in the gastrointestinal
tract following administration of varying doses of rapamycin
[26,27,28,29,30]. Importantly pharmacokinetic (PK) analysis of
rapamycin in dogs has not been reported. Defining exposure and
modifying dose, schedule and/or route of administration may
mitigate toxicity in dogs. Accordingly, before the dog could be
integrated within the development path of mTOR inhibitors in
osteosarcoma patients, preliminary studies with rapamycin in dogs
were necessary.
The Comparative Oncology Trials Consortium (COTC)
represents a large-scale collaborative effort of the NCI and
extramural academic veterinary oncology programs [24].
Through the COTC, the rapid evaluation of early cancer drugs
using biologically intensive trials has begun, utilizing the model
system of companion animals (dogs) with cancer. The study’s
primary objective was to identify a safe, pharmacokinetically and
pharmacodynamically relevant dose of rapamycin in tumor
bearing dogs, so as to comfortably include the dog in future
development studies. Results established that parenteral rapamy-
cin was well tolerated in dogs at PK exposures that allow
translation to human patients. All exposures of rapamycin
evaluated resulted in downward modulation of phosphorylation
of the mTOR target S6RP in tumors and PBMCs. Study data
provide the basis to include the dog in the study of mTOR
inhibitors as part of their development in pediatric osteosarcoma
and other cancers. On-going efforts in dogs are underway to
validate novel pharmacodynamic biomarkers of relevant clinical
exposure to rapamycin, to assess the impact of immunosuppressive
and non-immunosuppressive schedules of rapamycin in cancer,
and to assess the activity of rapamycin in the minimal residual
disease setting in osteosarcoma.
Results
Cell lines and in vitro inhibition with rapamycin
Little is known about the status of mTOR biology in canine
osteosarcoma [31]. Studies done in preparation for this trial
showed that components of the mTOR pathway, mTOR, p-S6, p-
4EBP1 are expressed in canine osteosarcoma cell lines and
primary tumors (data not shown). Using both western blot and
electrochemiluminescence (ECL) analysis, rapamycin inhibits
down-stream targets of mTOR in a dose-dependent fashion.
(Figure S1) [31]. These data supported the credentials of canine
osteosarcoma as a model for human osteosarcoma and more
broadly as a solid tumor sensitive to mTOR inhibitor therapy.
Study design and schedule
The study design was a dose escalation approach (Table 1:
Dose Escalation Cohorts and Table 2: Study Schedule)t o
define relevant exposures of rapamycin and/or maximally
tolerated dose (MTD) in dogs with appendicular osteosarcoma.
All dogs underwent a pre-treatment tumor biopsy and collection of
PBMC at study initiation. Dogs received a single intramuscular
dose of rapamycin and underwent 48-hour PK whole blood
collections. Dogs were then administered daily intramuscular
doses of rapamycin for 7 consecutive days at fixed dose. All had
post-treatment collection of tumor and PBMC. The defined study
period was 15 days. Safety, tumoral pharmacodynamic (PD)
Figure 1. The mTOR pathway is integral in cell metabolism and
protein translation in cancer. The mTOR pathway is the ‘‘nutrient
sensor’’ of the cell and proximate targets of the pathway are
responsible for both TOP and cap-dependent translation of proteins.
Many of these proteins have been shown to be important in cancer
progression, angiogenesis, autophagy and anti-apoptotic mechanisms.
Rapamycin inhibits mTOR (via TORC1) following the formation of a
complex with FKBP-12.
doi:10.1371/journal.pone.0011013.g001
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ship between PK and PD were study endpoints.
Dose Escalation Process and Patient Characteristics
Dogs were entered to rapamycin dose cohorts consisting of 3
dogs per cohort (n=22 enrolled, n=19 dogs completed study).
Escalation through 5 planned dose cohorts was based on
assessment of dose limiting toxicities (DLT) using VCOG
modified-CTCAE convention [32]. Age (range, 3.7–11.9 years;
median 7.9 years), sex (14 spayed females, 8 castrated males) and
breed (5 mixed-breed and 17 purebred) were recorded for all dogs
enrolled on study (Table 3: Patient Characteristics).
Parenteral administration of rapamycin was well
tolerated by tumor-bearing dogs
Hematologic and biochemical laboratory tests were collected at
baseline (Day 0) and weekly (Day 8 and Day 15) to evaluate the
safety of short-term rapamycin exposure. All data were reported
by contemporaneous electronic reporting (C3D) such that adverse
events were uniformly monitored, managed, and attributed within
this multi-center COTC trial design. Escalation of rapamycin,
from administered doses of 0.35mg/dog to 2.8mg/dog (IM, QD)
was well tolerated and a maximally tolerated dose (MTD) was not
defined (n=19).
No unexpected adverse events were noted. Self-limiting and
non-dose limiting toxicities (grade 1,2) that may have been
attributable to rapamycin included vomiting (n=2), diarrhea
(n=1), anorexia (n=2) and thrombocytopenia (n=1). There were
two febrile episodes reported n=1 at Day 7 (patient 0707) and
n=1 at Day 14 (patient 0204). The day 14 event was a result of a
second occult neoplasm. The Day 7 event although mild (grade 1),
was clinically relevant as it was concurrent with thrombocytopenia
(grade 2). This event was believed to be an idiosyncratic post-
operative reaction, and recovered without intervention. A first
event death at Day 10, one-day post-operatively (patient 0704) was
recorded. Necropsy of this case revealed cause of death to be
congestive heart failure due to occult cardiomyopathy exacerbated
by anesthesia and surgery. Although this event was not drug
related, three additional dogs were entered into this dose cohort
during the resolution of necropsy findings and attribution of the
event (cohort 4). No additional toxicities were observed in this
expanded cohort. There were no clinically significant neurological,
respiratory, renal, or biochemical toxicities related to the
treatment of the dogs with rapamycin. Two dogs withdrew from
study during the week of drug administration, one due to
intractable pain at the primary tumor site and one due to owner
request. Neither immunosuppression nor surgical incision healing
delays were reported during this short-term rapamycin treatment
or through the post-treatment observation period (Day 15).
Rapamycin administration in dogs with cancer resulted in
systemic exposures similar to those seen in human
patients
Serial rapamycin whole blood concentrations (ng/ml) were
measured for all dogs (0.01–0.08 mg/kg IM) on study by high-
pressure liquid chromatography (HPLC) with tandem mass
spectrometry (MS/MS) detection. Ten (10) samples per patient
were collected at 0, 30 minutes, 1,2, 6, 24 and 48 hours, after the
first rapamycin administration and then on days 8, 9 and 15 at 24-
hour trough time points. The Tmax ranged from 2–48hrs
indicating that the absorption of rapamycin after IM injection in
dogs was variable. Over the dose range studied, average
concentration – time curves (Figure 2A) and systemic exposure
(Cmax and AUC0–48h, Figure 2B) increased proportionally to
rapamycin dose (Figure 2 and Table 4). The terminal half-life of
rapamycin in dogs was greater than 60 hours. Steady state was not
Table 1. Rapamycin Dose Escalation cohorts in dogs with osteosarcoma.
Dose Cohort
Rapamycin dose cohorts
(7 day daily IM schedule
# of dogs
in cohort
Median weight
(kg)/cohort
Approximate rapamycin
dose administered IM QD
1 0.01 mg/kg IM daily 3 43.2 0.35 mg
2 0.02 mg/kg IM daily 4 36 0.70 mg
3 0.04 mg/kg IM daily 3 35.6 1.4 mg
4 0.06 mg/kg IM daily 7 38.5 2.1 mg
5 0.08 mg/kg IM daily 4 32.5 2.8 mg
doi:10.1371/journal.pone.0011013.t001
Table 2. Rapamycin Dose Escalation Study Schedule.
Action Pre tx Day ,0 Day 0 Day 1 Day 8 Day 15
Patient Eligibility X
Tumor Biopsies X X
Measurement of tumor burden (radiograph) X X
Digital photo of tumor X X
CBC/chemistry profile/UA X X X
PBMC collection X X X
Serum, plasma collection XXXX
Owner Assessment Form X X X
doi:10.1371/journal.pone.0011013.t002
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to steady state to be 12.5 days. Clearance could not be estimated
because the sampling interval was shorter than the half-life.
However, accumulation was evident at Day 15, seven days after
cessation of therapy (CD15, ng/ml), therefore clearance may be
lower than in humans [33]. At 0.06 mg/kg (approx 2.1 mg/day)
and 0.08 mg/kg (approx 2.8 mg/day) dose levels, median trough
concentrations on day 8 and 9 (CD8,C D9, ng/ml) were greater
than 10 ng/mL, the putative trough target concentration in
humans receiving rapamycin in the setting of transplantation [34].
In summary, translationally relevant exposures of rapamycin were
achieved in dogs with cancer (Figure 3).
Rapamycin administration resulted in both tumor and
PBMC modulation of mTOR targets
Modulation of mTOR pathway targets were evaluated in
matched tumor (Figure 4A.) and PBMC samples (Figure 4B.)t o
compare p-S6RP and p-AKT expression pre- and post-rapamycin
treatment. ECL techniques were utilized to accurately quantify the
relative percentage of phospho-protein over total protein (p/t) in
tumor and PBMC. Quality control assessments defined 10 tumor
and 8 PBMC samples eligible for evaluation. Rapamycin led to
.2-fold inhibition of tumoral p/t-S6RP (S240/S244) in 8/10 dogs
(Figure 4A., p=0.039). PBMC p/t-S6RP inhibition was highly
significant at Day 8 and was maintained through Day 15 (n=8,
Figure 4B.,p ,0.0001). Modulation of mTOR pathway targets
in PBMC and tumor samples were concordant. Interestingly,
marked post-treatment mTOR pathway inhibition was seen in
dogs from all dose cohorts, including the lowest dose cohorts
(0.01–0.02 mg/kg). It is unlikely that exposures generated from
rapamycin treatment in these lowest dose cohorts are clinically
active in patients. There was no relationship observed between
pharmacokinetic parameters (AUC0–48hr, trough concentration, or
Cmax) and decrease in pS6RP/t-S6RP in PBMC or tumor (data
not shown). This suggests that pS6RP is a highly sensitive
biomarker of any rapamycin exposure, but not likely a biomarker
of effective exposure or a likely predictor of future clinical
response.
Lack of p/t-AKT up-regulation in rapamycin treated
tumors
AKT is an important pro-survival pathway in a variety of tumor
types. Up-regulation of p-AKT has been suggested to be a
consequence of mTOR inhibition. In 9 tumor samples that passed
quality control assessments for ECL there was no post treatment
up-regulation of relative p/tAKT (S473) after 8 days of exposure
to rapamycin (p=0.069). (Figure 5) The influence of longer-term
rapamycin exposure on this pathway is unknown.
Discussion
Results of this study demonstrate that rapamycin can be
administered to dogs at pharmacokinetic exposures that are safe
and translationally relevant (i.e. achievable in human cancer
Table 3. Patient Characteristics.
Site Patient Dog’s Sex Age Breed Primary Disease Site Stage of Disease Cohort
CSU 0201 Spayed female 8.6 Rottweiler Humerus I 0.01 mg/kg IM daily
OSU 0601 Spayed female 5.1 Mixed Breed Tibia II 0.01 mg/kg IM daily
UW 0501 Castrated male 9.3 Weimaraner Radius 0.01 mg/kg IM daily
OSU 0602 Castrated male 5.7 Great Pyrenees Tibia II 0.02 mg/kg IM daily
OSU 0603 Spayed female 9.1 Weimaraner Humerus II 0.02 mg/kg IM daily
OSU 0604 Castrated male 5.9 Saint Bernard Radius II 0.02 mg/kg IM daily
UIL 0701 Castrated male 8.8 Irish Setter Humerus IIB 0.02 mg/kg IM daily
OSU 0605 Spayed female 11.9 Mixed Breed Humerus II 0.04 mg/kg IM daily
UIL 0702 Spayed female 8 Boxer Tibia IIB 0.04 mg/kg IM daily
UIL 0703 Spayed female 8.2 Mixed Breed Radius IIB 0.04 mg/kg IM daily
CSU 0202 Spayed female 3.7 Great Pyrenees Tibia II 0.06 mg/kg IM daily
CSU 0203 Spayed female 7.1 Mixed Breed Radius II 0.06 mg/kg IM daily
CSU 0204 Spayed female 4.6 Great Dane Radius II 0.06 mg/kg IM daily
CSU 0205 Spayed female 8.7 Labrador Retriever Humerus II 0.06 mg/kg IM daily
OSU 0606 Spayed female 10.2 Rottweiler Tibia 0.06 mg/kg IM daily
UIL 0704 Castrated male 6 Irish Wolfhound Tibia IIB 0.06 mg/kg IM daily
UIL 0705 Castrated male 3.9 Beagle Humerus IIA 0.06 mg/kg IM daily
CSU 0207 Castrated male 5.8 Rottweiler Humerus I 0.08 mg/kg IM daily
CSU 0208 Castrated male 11.7 Labrador Retriever Radius I 0.08 mg/kg IM daily
UIL 0706 Spayed female 6.1 Mixed Breed Radius IIB 0.08 mg/kg IM daily
UIL 0707 Spayed female 10.4 Greyhound Femur IIB 0.08 mg/kg IM daily
UIL 0708 Spayed female 7.8 Rottweiler Femur IIB 0.08 mg/kg IM daily
Site of enrollment: CSU=Colorado State University, UIL=University of Illinois, OSU=Ohio State University, UW=University of Wisconsin; WHO staging for canine
osteosarcoma: Stage I=low grade primary tumor, A=intracompartmental tumor, B=extracompartmental tumor, Stage II=high grade primary tumor/no metastatic
disease (N0 and M0), A=intracompartmental tumor (in marrow), B=extracompartmental tumor.
Stage III= low or high grade primary tumor with metastatic disease (N1 or M1), A=intracompartmental tumor, B=extracompartmental tumor.
doi:10.1371/journal.pone.0011013.t003
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mTOR pathway in canine tumors and PBMC without inducing
AKT phosphorylation. Inhibition of S6RP phosphorylation was a
highly sensitive marker of exposure to rapamycin, even in the
lowest dose cohorts, such that its pharmacodynamic modulation
was not dose dependent.
The biological behavior and histological features of canine and
human osteosarcoma are indistinguishable [25,35]. Both cancers
represent primary cancers of bone, occurring primarily in the
appendicular skeleton. Most importantly, cancers in both species
are characterized by metastasis. Despite complete surgical control
of the primary tumor, metastasis to the lungs is the most common
cause of death in human and canine osteosarcoma [35]. Recent
studies in our laboratory have extended the observation of
biological similarities through gene expression analysis of both
canine and human cancers [36]. The relevance of osteosarcoma as
a model for a highly metastatic human cancer, along with
preclinical data generated herein that supports the opportunity to
evaluate mTOR inhibitors in canine osteosarcoma, paves the way
for clinical evaluation of rapamycin and other mTOR inhibitors in
tumor bearing dogs as part of an integrated and comparative drug
development approach.
Many questions remain regarding the optimal use of mTOR
inhibitors in cancer and in pediatric osteosarcoma in particular.
Responses in clinical trials using mTOR inhibitors have been
sporadic and not necessarily predicted by cancer histology.
Furthermore modulation of traditional PD biomarkers such as
phospho-S6RP, as found in this study, is unlikely to define
clinically relevant exposures of rapamycin or rapalogs. This
finding was supported by recent PK-PD evaluations in human
patients with solid tumors that found phosphorylation of S6RP in
skin surrogates did not correlate with rapamycin dose or response
Figure 2. Rapamycin exposure in dogs with osteosarcoma is dose dependent. Serial rapamycin whole blood concentrations (ng/ml) were
measured by HPLC with MS/MS detection for all dogs that completed study (n=19). After a single parenteral dose of rapamycin, 7-point PK analysis
(samples collected at 0, 30 minutes, 1,2, 6, 24 and 48 hours) was performed. Over the dose range studied, A. average concentration – time curves for
each dose level, and B. rapamycin exposure (AUC0–48h) increased proportionally to dose.
doi:10.1371/journal.pone.0011013.g002
Table 4. Median (Range) Non-Compartmental Pharmacokinetic Parameters in dogs with cancer after 8 days of exposure to
rapamycin.
Dose Level N AUC0–48 Cmax Tmax C48h CD8 CD9 CD15 T1/2
mg/kg ngNhr/mL ng/mL h ng/mL ng/mL ng/mL ng/mL h
0.01 3 47.4 (31.9–60.2) 1.27 (0.79–2.92) 24 (24–48) 0.91 (0.56–2.92) 2.78 (1.77–3.39) 1.92 (0.5–3.14) 0.45 (0–0.89) 114.6
0.02 4 64.3 (44.9–67.3) 1.69 (1.21–1.82) 24 1.26 (1.11–1.55) 5.63 (5.4–5.65) 5.93 (4.42–7.15) 0.86 (0.78–0.95) 70.8 (23.2–88)
0.04 3 105.4 (96.9–308.9) 2.87 (2.39–18.2) 24 (2–24) 1.86 (1.38–2.19) 6.62 (3.18–9.72) 7.92 (3.2–10.1) 1.56 (0.32–1.91) 62.7 (17.6–88.6)
0.06 7 285.2 (158.2–381.8) 7.29 (3.87–17.8) 6 (2–24) 3.61 (2.11–4.73) 9.84 (6.49–17.6) 9.3 (7.9–16.6) 1.04 (0.87–3) 72.7 (58.2–95.8)
0.08 4 309.3 (188.9–533.0) 12.14 (5.36–21.1) 15 (2–24) 4.6 (3.94–5.45) 15.4 (15.1–19.6) 16.4 (8.65–21.4) 3.66 (2.51–4.81) 86.6 (76.7–96.5)
doi:10.1371/journal.pone.0011013.t004
Comparative Rapalog Modeling
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described and are required for successful development of this class
of compounds. Acquiring matched PK and PD (tumor and
surrogate PBMC measurements) for all dosing cohorts in this study
demonstrates a unique attribute of the comparative approach that
can aid in the discovery and validation of novel biomarkers that
may predict response to mTOR inhibitors. Elaborating on
exposure-dose-PD associations will be the focus of future modeling
of rapamycin and rapalogs development.
As an immunomodulator, concerns about the impact of
rapamycin on regulatory T cells (Tregs) and other negative
effectors of the immune system are of unique concern for cancer
patients. In this short-term study of rapamycin exposure in dogs
with osteosarcoma, there was no evident lymphopenia, increased
Figure 4. Rapamycin therapy inhibits tumoral and PBMC downstream targets of mTOR in a clinical setting. Modulation of mTOR
pathway targets were evaluated in matched tumor (A.) and PBMC samples (B.) to compare pS6RP pre- and post-rapamycin therapy.
Electrochemiluminescence (ECL) was utilized to accurately quantify phospho-protein status in tumor and PBMC. Quality control assessments defined
10 tumor and 8 PBMC samples eligible for evaluation. A. The red bars below the x-axis indicate patient dosing cohorts. Pre-treatment bars (purple)
represent p-S6RP tumor levels prior to rapamycin dosing and post-treatment bars (blue) represent Day 8 levels at tumor surgical excision. Rapamycin
led to .2-fold inhibition of tumoral p-S6RP in 8/10 dogs (A,p ,0.0001). B. PBMC phosphorylation of S6RP was significantly inhibited in 8/8 dogs
evaluated at Day 8 after rapamycin therapy and was maintained through Day 15 (7 days after the cessation of rapamycin therapy) (B,p ,0.0001).
Matched PBMC and tumor sample data were concordant. Marked post-treatment mTOR pathway inhibition was seen in dogs from all dose cohorts,
including the lowest dose cohorts (0.01–0.02 mg/kg), proving that p-S6RP is a very sensitive biomarker of rapamycin administration.
doi:10.1371/journal.pone.0011013.g004
Figure 3. Translationally relevant exposures of rapamycin were achieved in dogs with cancer. In this study, dogs in the 4
th (0.06 mg/kg,
approx 2.1 mg) and 5
th (0.08 mg/kg, approx 2.8 mg) dose cohorts had measurable trough levels $10 ng/ml. Trough concentrations in dogs with
osteosarcoma after 7 and 8 days (CD8,C D9, ng/ml) of rapamycin treatment are similar to those intended for human cancer patients. Translationally
relevant exposures of rapamycin are achievable in dogs with cancer, and support the use of the comparative approach in rapalog development.
doi:10.1371/journal.pone.0011013.g003
Comparative Rapalog Modeling
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reported. However it is likely that longer-term exposure would be
necessary to cause clinical immunosuppression. Additionally, an
optimal schedule for long-term exposures to rapamycin in cancer
patients must be characterized. Schedules for rapamycin in the
setting of immunosuppressive transplantation are not necessarily
ideal and may be deleterious as cancer therapies. Optimization of
schedule is considered a priority for future canine osteosarcoma
rapamycin studies to assess immunosuppression and to determine
what regime is most advantageous. Based on the success of this
effort, a follow-up evaluation in dogs with metastatic osteosarcoma
was launched. Indeed the study aimed to compare three schedules
of rapamycin therapy and evaluate chronic tolerability at a fixed
rapamycin dose. Chronic administration of this parenteral
formulation was not tolerable. Sterile abscess formation at the
site of intramuscular (IM) injection occurred and could not be
ameliorated by a change to subcutaneous (SQ) administration. In
addition, the long-term stability of the described formulation was
problematic, thus objectives to compare immune function,
evaluate PBMC AKT-mTOR axis modulation and determine if
rapamycin treatment is active in dogs with measurable metastatic
disease was impracticable. This parenteral formulation has been
abandoned in favor of oral dosing for schedule selection studies in
dogs. Recent anecdotal evidence has shown tolerability to oral
rapamycin dosing in dogs with cancer. Formal PK and tolerability
assessments with oral rapamycin formulations in dogs are
currently underway.
Rapamycin is the first generation agent in this class of
compounds. Rapalogs were developed to improve its solubility.
In fact, most are metabolized to rapamycin for their active form.
Beyond routes of administration and potency, is very unlikely that
the biology of rapamycin and rapalogs will be different. As such
these data can be translated to the evaluation of rapalogs in dogs.
That being said each new agent is a discrete drug and validation
studies will be needed to confirm their safety in dogs with cancer.
Additionally, the next phase mTOR kinase inhibitors are likely
distinct agents with some but not completely overlapping biologies.
Novel studies in dogs may elucidate these unique mechanisms of
action and also inform their development.
This work validates dogs with cancer to be relevant models in
researching rapalog drug development. Accelerated completion
and contemporaneous reporting of tumor bearing dog trials seizes
upon the timely opportunity to guide pivotal trial initiation in
pediatric sarcoma patients. Future randomized control studies of
rapamycin combined with chemotherapy in dogs with osteosar-
coma can inform our understanding of how best to use rapalogs in
microscopic disease, their most likely efficacious setting. By
answering critical adjuvant questions in the dog, results will
influence the design of planned Children’s Oncology Group
(COG) Phase III trials of rapamycin in combinational regimes.
Comparative oncology models may also allow further elucidation
of PK-PD relationships and provide imaging surrogates effective
for early response evaluation in this class of compounds.
Collectively these data will be integrated within the development
consideration of rapamycin and rapalogs for both canine and
human pediatric sarcoma and solid tumor patients.
Materials and Methods
Comparative Oncology Trials Consortium
The goals and infrastructure of the COTC have been recently
described [24,25]. This is the second clinical trial in dogs with
cancer conducted through this multi-institutional consortium. All
COTC trial data were reported electronically and contempora-
neously reviewed through a modified form of Oracle Clinical,
known as the Cancer Central Clinical Database (C3D), developed
through the NCI’s Center for Cancer Research (CCR) and
Cancer Bioinformatics Grid (CaBIG) and modified for use in
canine clinical trials [38].
Cell lines and in vitro inhibition with rapamycin
Immunoblots. Tumor cell lines (BW, SK-primary canine
osteosarcoma cell lines, Hong, SH, personal communication; and
MCF7, MDA231-human breast carcinoma; American Type
Culture Collection) were treated with (100nM for 4 hours) or
without rapamycin as described, then lysed in MSD lysis buffer
(see below) with complete lysis buffer with protease and
phosphatase inhibitors. Protein concentration of lysates was
Figure 5. Tumoral AKT phosphorylation is unchanged after short-term exposure to rapamycin in dogs with osteosarcoma. AKT is an
important pro-survival pathway in a variety of tumor types. In 9 tumor samples that passed quality control standards there was no significant
(p=0.069) post treatment up-regulation of pAKT (measured by ECL) after 8 days of exposure to rapamycin.
doi:10.1371/journal.pone.0011013.g005
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Scientific, Rockford, IL). Lysates were separated with Invitrogen
NuPage gels (Invitrogen, Carlsbad, CA) and transferred to
nitrocellulose membranes. The blots were probed for the
proteins of interest with specific antibodies followed by a
secondary antibody (Cell Signaling Technology, Inc, Danvers,
MA) and then incubated with SuperSignal chemiluminescence
substrate (Pierce). The blots were then exposed to Kodak Biomax
Light Film (Kodak, Rochester, NY). The antibodies against AKT
and p-AKT (Ser473), S6RP and p-S6RP, and actin were obtained
from Cell Signaling.
Trial eligibility and enrollment
Client-owned pet dogs with histologically confirmed, localized
appendicular osteosarcoma, favorable performance status (grade 0
or 1 modified ECOG performance status), and informed owner
consent were eligible for enrollment. Eligibility criteria required a
measurable tumor amenable to incisional biopsy and surgical
resection, and a 72-hour washout from any previous non-steroidal
anti-inflammatory drug (NSAID) administration. Physical exam-
ination, laboratory [complete blood count (CBC), serum biochem-
ical profile, urinalysis (UA)], and imaging studies were performed
to evaluate eligibility prior to enrollment. Exclusion criteria
removed dogs weighing less than 15 kg, those with significant
co-morbidities (such as renal, liver, and heart failure or
coagulopathy), history of inflammatory bowel disease, chronic
gastroenteritis, or concurrent chemotherapy, radiation therapy, or
biological therapy. Tumor staging included thoracic radiographs
performed prior to enrollment. All dogs were evaluated uniformly
and treated within a defined clinical protocol with Institutional
Animal Care and Use Committee (IACUC) approval at each
COTC enrollment site (Colorado State University, University of
Illinois, Ohio State University and University of Wisconsin-
Madison). The NCI-Comparative Oncology Program (COP)
reviewed the eligibility screening and approved trial entry of each
patient.
Rapamycin administration, monitoring, and safety
assessment
Dogs underwent a complete physical examination, CBC, serum
biochemical profile, UA and pre-treatment biopsies at Day 0. Vital
signs (core temperature, pulse, respiratory rate) were recorded at
baseline. Dogs received parenteral (IM) rapamycin initially on Day
0 in the early morning and remained hospitalized for serial serum/
plasma and whole blood collections over a 48-hour period. Dogs
were discharged into the care of their owners and subsequently
received rapamycin IM at home via owner administration for 7
consecutive days (once daily). Owners completed an Owner
Assessment Form on Days 0, 8 and 15 to record impressions of
their dog’s clinical status throughout the study period.
Definition of acute and chronic toxicities of single and multiple
doses of rapamycin was a major goal of this study. Blood samples
were collected to define hematologic and biochemical DLT. CBC,
biochemical profile and urinalysis were evaluated at Day 0, and
then weekly (pre-operatively at Day 8 and Day 15) to define safety.
The Veterinary Cooperative Oncology Group Common Toxicity
Criteria for Adverse Events (VCOG-CTCAE) was used to
determine DLT, defined as any grade 3 or grade 4 (hematologic
or non-hematologic) events [32]. DLT toxicity in 1/3 dogs in a
cohort (33%) necessitated cohort expansion to ensure tolerability.
MTD was defined as one dose level below the maximum achieved
in dose-escalation. Any and all adverse events were collected
within the electronic database reporting system (C3D) following
strict one-week reporting timelines.
Rapamycin formulation
Rapamycin (R-5000, MW=914.17; C51H79NO13, .99% pure)
was purchased from LC Laboratories (www.lclabs.com, Woburn,
MA). The University of Arizona College of Pharmacy (SY)
formulated a parenteral rapamycin solution (2 mg/ml) via the
recipe in Table 5. The pH of the final formulation was 5.09 and
density 1.01 g/ml. The formulation was filtered through a 250ml
0.2mm sterile vacuum filter system (Corning Inc). HPLC analysis
was used to verify drug concentration using a standard curve of
rapamycin spike in concentrations (0.05, 0.1, 0.25, 0.5 mg/ml).
Stability studies consisted of HPLC analysis at time zero (t=0) and
after 1-month storage at different temperatures. Stability was
maintained at 4 C for 1 month. A portion of the remaining
volume was held at 4uC for 6-month stability studies, again
showing stability of this initial (COTC003) formulation at 4 C.
Although some precipitation was observed due to low solubility, it
was overcome with sonication. Total of 3 containers, each
containing 250 ml, 250 ml and 200 ml respectively (total of
750 ml), were shipped to the NCI-COP for distribution to COTC
sites. A 5 ml aliquot (before filtration) was shipped separately for
endotoxin testing. Endotoxin was measured prior to rapamycin
patient use, using Limulus Amebocyte Lysate QCL-1000H kits
(Cambrex, Inc., Watersville, MD) and results showed negligible
levels.
Reformulation for chronic dose study
The formulation for rapamycin was augmented for the chronic
dose study (Dr. Samuel Yalkowsky, University of Arizona College
of Pharmacy) from the original recipe used in COTC003
(described above). In this new formulation, additional benzoic
acid buffer (total of 5% w/v) was added and heat used to ensure
rapamycin dissolution. Post hoc stability assessments in two
laboratories (SY and DG) revealed degradation of the parent
drug. Chromatographs showed two resultant peaks: the first
consistent with rapamycin (RT=0.55–0.56 min) and a second
unknown peak (RT=0.96–0.99 min) (via DS SCIEX 3200 Q-
TRAP LC/MS/MS system equipped with a HPLC column (DG)).
These were repeated for verification with the same result.
Rapamycin Pharmacokinetic Sampling
Serial whole blood (5 ml, with K3 EDTA anticoagulant)
samples were obtained by venipuncture prior to and 0.5, 1, 2, 6,
24 and 48 hours after the first dose of rapamycin. The second dose
of rapamycin was administered after the 48-hour sample was
obtained. Subsequent doses were administered on days 3–8.
Additional pharmacokinetic samples were obtained on days 8
(192h, day of definitive resection) and 9 (hr 216, after last day of
dosing) and 15 (360 hr). When applicable, all whole blood
Table 5. Rapamycin Formulation.
Ingredients Formula Ideal Amount Actual Amount
Rapamycin 1800.0 mg 1800.0 mg 1801.49 mg
Ethanol 10.0% 90.0 ml 90.0 ml
Propylene glycol 40.0% 360.0 ml 360.0 ml
Benzyl alcohol 1.5% 13.5 ml 13.5 ml
Benzoate buffer pH 4.05 5.0% 45.0 ml 45.0 ml
Total Volume q.s. WFI 900.0 ml 900.0 ml 900.0 ml
Final Concentration 2.0 mg/ml 2.0 mg/ml 2.002 mg/ml
doi:10.1371/journal.pone.0011013.t005
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rapamycin administration. Whole blood was transferred to
cyrovials and stored at 280uC until analysis. Whole blood, serum
and plasma were collected from all patients. Serum and
plasma samples were stored for post-hoc hypothesis generating
assessments.
Rapamycin Pharmacokinetic Assay and Analysis
A method for determining rapamycin concentrations in dog
whole blood was developed by Covance, Inc (Covance Bioana-
lytical Services, LLC, Indianapolis, IN) based on a previous
protocol for human whole blood rapamycin pharmacokinetics
(Covance 2100-358). Rapamycin was extracted from dog whole
blood by protein precipitation followed by solid-phase extraction.
The eluate was analyzed using HPLC with MS/MS detection.
Rapamycin, the internal standard (ISTD), tacrolimus, and normal
canine whole blood were used for calibration and quality controls.
The standard curve range for rapamycin is from 0.250 to 50.0 ng/
mL, using a whole blood sample volume of 0.200 mL. Clinical
sample results were calculated using peak area ratios and
calibration curves were generated using a weighted (1/x
2) linear
least-squares regression. The calibration standards and quality
control samples were within acceptance criteria and the assay
method validated with repeatable precision and accuracy. All data
were acquired, processed, and reported using Applied Biosystems/
MDS-Sciex Analyst Version 1.4 software (www.lifetechnologies.
com, Carlsbad, CA).
Rapamycin concentration-time data were analyzed using non-
compartmental methods. The peak rapamycin concentration
(Cmax)) and time to peak concentration (Tmax) were determined
from concentration-time plot of each subject’s data. Area under
the concentration time curve to the time point measured at 48hr
after the first dose (AUC0–48h) was calculated with the linear
trapezoidal method. The terminal rate constant was derived from
the slope of the natural log transformed concentrations and times
on the terminal elimination phase of the decay curve. Terminal
elimination half-life was calculated by dividing 0.693 by the
terminal rate constant. The relationship of pharmacokinetic
parameters and pharmacodynamic variables were examined using
scatter plots.
Tumor collections
Serial biopsies were required from all dogs to evaluate mTOR
target pharmacodynamics in tumors at baseline and their
modulation following rapamycin therapy. Biopsy techniques were
prospectively defined by standard operating procedures (SOPs)
applied uniformly at all participating COTC sites. Incisional pre-
treatment biopsies were collected (11 gauge Jamshidi) before
rapamycin administration, with three (3) samples obtained at
various planes within the tumor to capture natural disease
heterogeneity. Each of these sections were divided equally and
one half fixed in 10% formalin and the other half flash frozen in
liquid nitrogen. Post treatment samples were obtained at surgical
excision of the tumor via standard techniques/amputation with
biopsies collected within 20 minutes of limb removal. Again, three
(3) sections of the tumor were sampled at various angles/planes,
divided and stored as above. After the 3 sections were taken the
whole tumor was resected from the limb and divided into two (2)
equal portions. Half of the resected tumor was submitted for
standard histopathologic evaluation at the enrolling COTC
institution, and the other half subdivided into two equal portions
for formalin fixation and flash freezing. After 24 hours of fixation
formalin samples were transferred to 80% ethanol and stored at
4 C. Frozen samples were stored at 280 C. All tissue samples
were shipped to the NCI-COP at end of the study for batch
evaluation.
PBMC Collections
PBMC collections were used for the assessment of correlative
PD endpoints (mTOR and down stream pathway inhibition after
rapamycin treatment). PBMCS were collected in two (2) 8 ml BD
CPT vacutainers (Becton Dickinson, Franklin Lakes, NJ) with
sodium heparin, each filled completely with whole blood. They
were centrifuged for one hour, the aqueous portion transferred
into 15 ml conical tubes, and shipped at room temperature to the
NCI-COP on the same day as their collection.
Protein lysates were made from these samples. Samples were
brought up to a volume of 15mL using 16PBS. A cell pellet was
obtained by centrifuging for 15 minutes at 300 rcf (around 1200–
1500 rpm). Supernatant was aspirated without disturbing the cell
pellet. To lyse the red blood cells, 500uL of DEPC treated water
was added to the pellet and pipetted up and down five times. Then
9.5mL of 16 PBS was quickly added. Samples were centrifuged
for 10 minutes at 300 rcf and supernatant was aspirated. If red
blood cells could be seen at this point, the process of lysing red
blood cells was repeated. Once a white pellet was isolated, 200uL
of 16PBS was added and cells were transferred to an Eppendorf
tube and stored at 280uC for future ECL analysis.
Pharmacodynamic Assessments
Electrochemiluminescence assays. The samples (cell lines,
tumor, PBMC) used for ECL were prepared based on the Meso-
Scale Discovery (MSD) lysate preparation protocol (Meso-Scale
Discovery, Gaithersburg, MD) using complete lysis buffer with
protease and phosphatase inhibitors. For quantitative analysis of
phospho-proteins, duplex t/p-AKT (S473) and duplex t/p-S6RP
(S240/S244) were obtained from MSD, used following
manufacturer’s instructions, and read with Sector Imager 2400
(MSD). A total of 25 ug of lysates were used per well for the duplex
assays. Out of the 19 paired tumor biopsies analyzed, 9 were
excluded due to values below the detection limit, of which 8 were
from one trial site. Large variation (100-fold) was seen with total
S6RP in biopsies therefore the ratio between p-S6RP/t-S6RP was
used for more appropriate statistical analysis. PBMC from 8
patients were analyzed for p-S6RP/t-S6RP and all data was
shown.
Histopathology Review
Formalin fixed tumor biopsies were paraffin embedded in
blocks, sectioned and stained with hematoxylin and eosin. A single
veterinary pathologist (TO) reviewed all samples for tumor
integrity and presence of necrosis. This analysis guided matched
frozen sample selection for ECL.
Supporting Information
Figure S1 Validation of rapamycin-mediated inhibition of p-
S6RP and quantitative electrochemiluminescence assays in canine
osteosarcoma A. Immunoblot shows rapamycin-mediated
(100 nM) inhibition of p-S6RP in two canine osterosarcoma cell
lines (BM, SK) and human breast cancer cell lines (MCF7 and
MDA231). Controls were Jurkat cells treated with LY (2) or PMA
(+). B. Quantitative determination of total and p-S6RP (S240/244)
with electrochemiluminescence (ECL) assay. C. Quantification of
ECL results illustrate that treatment with rapamycin results in
approximately 506 reduction of p/t-S6RP in two canine
osteosarcoma cell lines (BW and SK; p/t-S6RP Rapa %)
compared to untreated controls (BW and SK; p/t-S6RP ctrl %).
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